These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention? Fox DJ; Kibiro M; Eichhöfer J; Curzen NP Postgrad Med J; 2005 Jun; 81(956):401-3. PubMed ID: 15937208 [TBL] [Abstract][Full Text] [Related]
7. Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. Steg PG; Iung B; Feldman LJ; Cokkinos D; Deckers J; Fox KA; Keil U; Maggioni AP Heart; 2002 Jul; 88(1):20-4. PubMed ID: 12067934 [TBL] [Abstract][Full Text] [Related]
8. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Isles CG; Paterson JR QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551 [TBL] [Abstract][Full Text] [Related]
9. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events Lancet; 2001 Mar; 357(9261):995-1001. PubMed ID: 11293642 [TBL] [Abstract][Full Text] [Related]
10. Status of secondary prevention in patients undergoing coronary revascularization. Allen JK; Blumenthal RS; Margolis S; Young DR Am J Cardiol; 2001 May; 87(10):1203-6: A7. PubMed ID: 11356400 [No Abstract] [Full Text] [Related]
11. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. Vermeer NS; Bajorek BV J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and correlates of non-optimal secondary medical prevention in patients with stable coronary artery disease. Meurice T; Tricot O; Lemesle G; Deneve M; Lejeune P; Biausque F; Cordier C; Savoye C; Hennebert O; Taghipour K; Sivery B; Pruvost P; Alaoui M; Carpentier L; Segrestin B; Lamblin N; Bauters C Arch Cardiovasc Dis; 2015; 108(6-7):340-6. PubMed ID: 25858539 [TBL] [Abstract][Full Text] [Related]
13. Secondary prevention of coronary heart disease in the elderly. Dornbrook-Lavender KA; Roth MT; Pieper JA Ann Pharmacother; 2003 Dec; 37(12):1867-76. PubMed ID: 14632542 [TBL] [Abstract][Full Text] [Related]
14. Summaries for patients. Risk factors and treatment in women with coronary artery disease. Ann Intern Med; 2003 Jan; 138(2):I10. PubMed ID: 12529114 [No Abstract] [Full Text] [Related]
15. The impact of pharmacist-initiated interventions in improving acute coronary syndrome secondary prevention pharmacotherapy prescribing upon discharge. Hassan Y; Kassab Y; Abd Aziz N; Akram H; Ismail O J Clin Pharm Ther; 2013 Apr; 38(2):97-100. PubMed ID: 23441979 [TBL] [Abstract][Full Text] [Related]
16. Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey. Persell SD; Zei C; Cameron KA; Zielinski M; Lloyd-Jones DM Arch Intern Med; 2010 Mar; 170(5):470-7. PubMed ID: 20212185 [TBL] [Abstract][Full Text] [Related]
17. Secondary prevention in coronary heart disease. Effects of statins have been in addition to those of aspirin and beta blockers. Morrell J BMJ; 1999 May; 318(7195):1419-20. PubMed ID: 10334767 [No Abstract] [Full Text] [Related]
18. [Secondary prevention of acute coronary syndromes: are we following correctly the guidelines?]. Casella G; Greco C; Maggioni AP; Di Pasquale G G Ital Cardiol (Rome); 2006 Mar; 7(3):176-85. PubMed ID: 16572983 [TBL] [Abstract][Full Text] [Related]
19. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals. Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644 [TBL] [Abstract][Full Text] [Related]
20. Pharmacologic therapies after myocardial infarction. Rapaport E; Gheorghiade M Am J Med; 1996 Oct; 101(4A):4A61S-69S; discussion 4A69S-70S. PubMed ID: 8900339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]